Grifols begins European launch of Xembify to treat immunodeficiencies

3 July 2023

Barcelona, Spain-based plasma-derived medicine specialist Grifols (MCE: GRF) says it has now started marketing Xembify, its 20% subcutaneous immunoglobulin, in Spain.

This plasma medicine is indicated for treating primary immunodeficiencies (PID) and certain secondary immunodeficiencies (SID), which are expected to grow significantly in the coming years.

Grifols noted that Spain is the first country in the European Union where the product is available, although it was already approved last year by the health authorities of several European countries and the UK. Grifols plans to expand the number of countries with access to Xembify over the next year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK